Targeted radiotherapy of brain tumours

British Journal of Cancer

Volumn 90, Issue 8, 2004, Pages 1469-1473

  Zalutsky, M R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anaplastic astrocytoma; Glioblastoma multiforme; Glioma; Radioimmunotherapy; Radiotherapy

Indexed keywords

BIOTIN DERIVATIVE; CHIMERIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY 81C6 AT 211; MONOCLONAL ANTIBODY 81C6 I 131; MONOCLONAL ANTIBODY BC2 I 131; MONOCLONAL ANTIBODY BC2 Y 90; MONOCLONAL ANTIBODY BC4 BIOTIN Y 90; MONOCLONAL ANTIBODY BC4 I 131; MONOCLONAL ANTIBODY BC4 Y 90; PROTEIN ANTIBODY; SOMATOSTATIN DERIVATIVE; TENASCIN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ALTERNATIVE MEDICINE; ANTIBODY SPECIFICITY; BLOOD TOXICITY; BRACHYTHERAPY; BRAIN TISSUE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL SPECIFICITY; CLINICAL TRIAL; DOSIMETRY; DRUG SELECTIVITY; GLIOBLASTOMA; HUMAN; INTERSTITIAL RADIATION; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION INJURY; RADIOIMMUNOTHERAPY; RADIOSURGERY; SHORT SURVEY; SIDE EFFECT; TUMOR LOCALIZATION; ASTROCYTOMA; BRAIN TUMOR; METHODOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL TRIALS; GLIOBLASTOMA; HUMANS; RADIATION INJURIES; RADIOIMMUNOTHERAPY;

EID: 2442457534     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601771     Document Type: Short Survey

References (29)

1. Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong T, Friedman HS, Garcia-Tuner A, Herndon II JE, DeLong D, McLendon RE, Zhao X-G, Pegram CN, Bigner DD, Zalutsky MR (2000) Dosimetry and dose-response relationships in newly diagnosed patients treated with iodine-131-labeled anti-tenacin monoclonal antibody therapy. Int J Radiat Oncol Biol Phys 46: 947-958
2. Akabani G, McLendon RE, Bigner DD, Zalutsky M (2002) Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int J Radiat Oncol Biol Phys 4: 1259-1275
3. Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I, Zardi L (1993) Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 332: 39-43
4. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, Mclendon RE, Bigner SH, Zhao X-G, Pegram CN, Wikstrand CJ, Herndon II JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR (1998) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16: 2202-2212
5. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD (1983) Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43: 2796-2805
6. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black T, Lazzaro B, Nair S, McCormack T, Nieves J, Morabito M, Eshleman J (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22: 225-230
7. Cokgor I, Akabani G, Kuan C-T, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao X-G, Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon II JE, Provenzale JM, Zalutsky MR, Bigner DD (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18: 3862-3872
8. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710
9. De Santis R, Anastasi AM, Alessio V D, Pellicia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P (2003) Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT). Br J Cancer 88: 996-1003
10. Goetz C, Riva P, Poepperl G, Gildehaus FJ, Hischa A, Tatsch K, Reulen H-J (2003) Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neuro-Oncol 62:321-328
11. Goldbrunner RH, Bernstein JJ, Tonn J-C (1999) Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir. 141: 295-305
12. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G (2002) Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86: 207-212
13. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH (2002) Clinical impact and functional aspects of Tenascin-C expression during glioma progression. Int J Cancer 98: 362-369
14. 3-octreotide (DOTA-TOC). Swiss Med Wkly 131: 640-644
15. 90Y moabs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. Int J Radiat Oncol Biol Phys 40: 835-844
16. Nguyen TT, Pannu YS, Sung C, Dedrick RL, Walbridge S, Brechbiel MW, Garmestani K, Beitzel M, Yordanov AT, Oldfield EH (2003) Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 98: 584-590
17. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16: 227-235
18. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20: 1389-1397
19. Reist CJ, Bigner DD, Zalutsky MR (1998) Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res 4: 2495-2502
20. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo, M (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27: 601-609
21. Schold SC##Jr, Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, Bigner SH, Bigner DD (1993) Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 28: 488-496
22. 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med 29: 486-493
23. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018
24. Wikstrand CJ, Zalutsky MR, Bigner DD (2001) Therapy of brain tumors with radiolabeled antibodies. In Brain Tumor Immunotherapy, Liau LM, Becker DP, Cloughsey TF, Bigner DD (eds) pp 205-229. Totowa, NJ: Humana Press
25. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WKA (1999) Outcomes and factors in recurrent glioma patients enrolled onto phase II trials. J Clin Oncol 17: 2572-2578
26. Zalutsky M, Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McClendon R, Quinn J, Rich J, Penne K, Sampson J, Shafman T, Wong T, Bigner D (2002) Astatine-211 labeled human/mouse chimeric antitenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: Phase I study. Neuro-Oncol 4: S103 (abstract)
27. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD (1989) Pharmacokinetics and tumor localization of 1311-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49: 2807-2813 1989
28. 2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50: 4105-4110
29. Zalutsky MR, Vaidyanathan G (2000) Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle therapy. Current Pharm Design 6: 1433-1455